Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- Product: Vyleesi (bremelanotide injection) 1.75 mg/0.3 mL
- Route: Subcutaneous injection via autoinjector (abdomen or thigh)
- Dosing: 1.75 mg as needed, ≥45 min before anticipated sexual activity
- Maximum: 1 dose/24 hours; ≤8 doses/month
- Discontinue if no symptom improvement after 8 weeks
- Contraindicated in uncontrolled hypertension or known cardiovascular disease